SIDEBAR: Highlighted Abstracts to Watch in San Antonio 

Get Permission

  • S1-01. Piccart-Gebhart M, Holmes AP, de Azambuja E, et al: The association between event-free survival and pathological complete response to neoadjuvant lapatinib, trastuzumab or their combination in HER2-positive breast cancer. Survival follow-up analysis of the NeoALTTO study (BIG 1-06)
  • S1-02. Hurvitz S, Miller JM, Dichmann R, et al: Final analysis of a phase II 3-arm randomized trial of neoadjuvant trastuzumab or lapatinib or the combination of trastuzumab and lapatinib, followed by six cycles of docetaxel and carboplatin with trastuzumab and/or lapatinib in patients with HER2+ breast cancer (TRIO-US B07)
  • S1-03. Slamon DJ, Swain SM, Buyse M, et al: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer
  • S1-04. Tolaney SM, Barry WT, Dang CT, et al: A phase II study of adjuvant paclitaxel and trastuzumab (APT trial) for node-negative, HER2-positive breast cancer
  • S1-05. Loi S, Michiels S, Salgado R, et al: Tumor infiltrating lymphocytes indicate trastuzumab benefit in early-stage HER2-positive breast cancer
  • S1-06. Denkert C, Loibl S, Salat C, et al: Increased tumor-associated lymphocytes predict benefit from addition of carboplatin to neoadjuvant therapy for triple negative and HER2-positive early breast cancer in the GeparSixto trial (GBG 66)
  • S1-07. Adams S, Gray R, Demaria S, et al: Prognostic value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199
  • S2-01. Kunkler IH, Williams LW, Jack W, et al: The PRIME 2 trial: Wide local excision and adjuvant hormonal therapy ± postoperative whole breast irradiation in women ≥ 65 years with early breast cancer managed by breast conservation
  • S2-02. Badwe R, Parmar V, Hawaldar R: Surgical removal of primary tumor and axillary lymph nodes in women with metastatic breast cancer at first presentation: A randomized controlled trial
  • S2-03. Soran A, Ozmen V, Ozbas S: Early follow up of a randomized trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer
  • S4-04. Vora SR, Kim N, Costa C, et al: Overcoming resistance to PI3K inhibitors in PIK3CA mutant breast cancer using CDK4/6 inhibition: Results from a combinatorial drug screen
  • S4-05. Shao Z-M, Jiang Y, Yu K-D: Exome sequencing identifies shift in TP53 and PIK3CA mutation status after paclitaxel-based neoadjuvant chemotherapy in breast cancer
  • S4-06. Loibl S, Denkert C, Schneeweis A, et al: PIK3CA mutation predicts resistance to anti-HER2/chemotherapy in primary HER2-positive/hormone-receptor-positive breast cancer—prospective analysis of 737 participants of the GeparSixto and GeparQuinto studies
  • S5-01. Sikov WM, Berry DA, Perou CM, et al: Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance)
  • S5-02. Rugo HS, Olopade O, DeMichele A, et al: Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 TRIAL
  • S5-04. Mackey JR, Ramos-Vazquez M, Lipatov O, et al: Primary results of ROSE/TRIO-12, a randomized placebo controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer
  • S5-07. Smerage JB, Barlow WE, Hayes DF, et al: SWOG S0500 – A randomized phase III trial to test the strategy of changing therapy versus maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell levels at first follow-up assessment
  • S6-01. Balko JM, Giltnane JM, Schwarz LJ, et al: JAK2 amplifications are enriched in triple negative breast cancers after neoadjuvant chemotherapy and predict poor prognosis
  • S6-02. Symmans WF, Wei C, Gould R, et al: Long-term prognostic value of residual cancer burden classification following neoadjuvant chemotherapy
  • S1-10. Smith RA, Duffy S, Chen TH-H, et al: Disparities in the estimates of benefits and harms from mammography: Are the numbers really different?
  • OT2-01. Malorni L, Sanna G, Pestrin M, et al: Phase 2 study of palbociclib (CDK 4/6 inhibitor) for ER positive, HER2- negative post-menopausal advanced breast cancer patients recurring after hormonal therapy (to reverse endocrine resistance - TREnd trial)
  • OT2-6-11. von Minckwitz G, Bear H, Bonnefoi H, et al: PENELOPE: Phase III study evaluating palbociclib (PD-0332991), a cyclin-dependent kinase (CDK) 4/6 inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy (GBG-78/BIG1-13)
  • OT3-2-11. Chumsri S, Tait N, Shetty J, et al: A phase II study of letrozole and lapatinib followed by an addition of everolimus in postmenopausal women with advanced endocrine resistant breast cancer
  • P2-16-20. Clark AS, Lal P, Tan KS, et al: Biomarkers to predict response to the CDK 4/6 inhibitor, palbociclib (PD 0332991) in a single-agent phase II trial in advanced breast cancer ■

Related Articles

Program Co-Directors Highlight Abstracts of Interest for the Upcoming 2013 San Antonio Breast Cancer Symposium

The Co-Directors of the 2013 CTRC-AACR San Antonio Breast Cancer Symposium, which will be held December 10–14, 2013, have highlighted what they consider to be the most important abstracts to be presented at the Symposium. In a telebriefing in advance of the December meeting, C. Kent Osborne, MD,...




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.